Insider Selling: CytomX Therapeutics, Inc. (CTMX) Director Sells $242,700.00 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Director Frederick W. Gluck sold 10,000 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $24.27, for a total transaction of $242,700.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of CytomX Therapeutics, Inc. (NASDAQ CTMX) opened at 21.50 on Monday. The firm has a 50-day moving average of $17.37 and a 200 day moving average of $15.69. CytomX Therapeutics, Inc. has a 52-week low of $9.85 and a 52-week high of $24.67. The firm’s market cap is $792.64 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. On average, equities analysts predict that CytomX Therapeutics, Inc. will post ($1.47) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: CytomX Therapeutics, Inc. (CTMX) Director Sells $242,700.00 in Stock” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/09/insider-selling-cytomx-therapeutics-inc-ctmx-director-sells-242700-00-in-stock.html.

A number of brokerages recently issued reports on CTMX. BidaskClub cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Finally, Bank of America Corporation raised their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $32.67.

Several hedge funds have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of CytomX Therapeutics by 0.6% in the second quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock worth $85,444,000 after acquiring an additional 34,732 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of CytomX Therapeutics by 65.7% in the first quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock worth $26,434,000 after acquiring an additional 606,896 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of CytomX Therapeutics by 12.2% in the second quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock worth $14,323,000 after acquiring an additional 100,607 shares during the last quarter. EcoR1 Capital LLC bought a new position in shares of CytomX Therapeutics in the first quarter worth about $13,729,000. Finally, Redmile Group LLC lifted its holdings in shares of CytomX Therapeutics by 2.4% in the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after acquiring an additional 16,500 shares during the last quarter. 59.97% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

NASDAQ CTMX) opened at 21.50 on Monday. The firm has a 50-day moving average of $17.37 and a 200 day moving average of $15.69. CytomX Therapeutics, Inc. has a 52-week low of $9.85 and a 52-week high of $24.67. The firm’s market cap is $792.64 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. On average, equities analysts predict that CytomX Therapeutics, Inc. will post ($1.47) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: CytomX Therapeutics, Inc. (CTMX) Director Sells $242,700.00 in Stock” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/09/insider-selling-cytomx-therapeutics-inc-ctmx-director-sells-242700-00-in-stock.html.

A number of brokerages recently issued reports on CTMX. BidaskClub cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Finally, Bank of America Corporation raised their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $32.67.

Several hedge funds have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of CytomX Therapeutics by 0.6% in the second quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock worth $85,444,000 after acquiring an additional 34,732 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of CytomX Therapeutics by 65.7% in the first quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock worth $26,434,000 after acquiring an additional 606,896 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of CytomX Therapeutics by 12.2% in the second quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock worth $14,323,000 after acquiring an additional 100,607 shares during the last quarter. EcoR1 Capital LLC bought a new position in shares of CytomX Therapeutics in the first quarter worth about $13,729,000. Finally, Redmile Group LLC lifted its holdings in shares of CytomX Therapeutics by 2.4% in the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after acquiring an additional 16,500 shares during the last quarter. 59.97% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply